BIORESTORATIVE THERAPIES INC. - COMMON STOCK

BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication

06 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease

05 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on Dec. 5-6, 2022

29 Nov 2022 11:20:00 By Nasdaq GlobeNewswire

BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022

16 Nov 2022 08:56:00 By Nasdaq GlobeNewswire

BioRestorative Therapies CEO Lance Alstodt to be Interviewed on Famela and Friends Talk Radio Show

20 Oct 2022 09:30:00 By Nasdaq GlobeNewswire

BioRestorative Therapies to Present at the Dawson James Securities 7th Annual Small Cap Growth Conference

28 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies to Participate in the Roth Inaugural Healthcare Opportunities Conference

27 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14

07 Sep 2022 07:00:02 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

30 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

22 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces Clinical Site Initiation for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

13 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Hosts Principal Investigator Meeting for its BRTX-100® Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

29 Apr 2022 08:00:01 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

18 Apr 2022 08:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces cGMP Cell Manufacturing Facility Certification

04 Apr 2022 08:00:02 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces Research Collaboration with Professor Tore Bengtsson to Evaluate Heat Production of its ThermoStem® Program

10 Mar 2022 08:00:01 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces Notice of Allowance on Key Patent for its BRTX-100® Disc Program

16 Feb 2022 08:30:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces it has Initiated its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease – Site Selection Underway

07 Feb 2022 09:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies to Ring Nasdaq Stock Market Closing Bell

07 Feb 2022 07:45:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces Notice of Allowance for New Patent Application in Japan and Expansion of ThermoStem® IP Portfolio

02 Feb 2022 08:00:01 By Nasdaq GlobeNewswire